FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313509721> ?p ?o ?g. }

• W4313509721 endingPage "131" @default.
• W4313509721 startingPage "131" @default.
• W4313509721 abstract "Zika virus (ZIKV) pandemic and its implication in congenital malformations and severe neurological disorders had created serious threats to global health. ZIKV is a mosquito-borne flavivirus which spread rapidly and infect a large number of people in a shorter time-span. Due to the lack of effective therapeutics, this had become paramount urgency to discover effective drug molecules to encounter the viral infection. Various anti-ZIKV drug discovery efforts during the past several years had been unsuccessful to develop an effective cure. The NS2B-NS3 protein was reported as an attractive therapeutic target for inhibiting viral proliferation, due to its central role in viral replication and maturation of non-structural viral proteins. Therefore, the current in silico drug exploration aimed to identify the novel inhibitors of Zika NS2B-NS3 protease by implementing an e-pharmacophore-based high-throughput virtual screening. A 3D e-pharmacophore model was generated based on the five-featured (ADPRR) pharmacophore hypothesis. Subsequently, the predicted model is further subjected to the high-throughput virtual screening to reveal top hit molecules from the various small molecule databases. Initial hits were examined in terms of binding free energies and ADME properties to identify the candidate hit exhibiting a favourable pharmacokinetic profile. Eventually, molecular dynamic (MD) simulations studies were conducted to evaluate the binding stability of the hit molecule inside the receptor cavity. The findings of the in silico analysis manifested affirmative evidence for three hit molecules with -64.28, -55.15 and -50.16 kcal/mol binding free energies, as potent inhibitors of Zika NS2B-NS3 protease. Hence, these molecules holds the promising potential to serve as a prospective candidates to design effective drugs against ZIKV and related viral infections." @default.
• W4313509721 created "2023-01-06" @default.
• W4313509721 creator A5003144386 @default.
• W4313509721 creator A5010154794 @default.
• W4313509721 creator A5012496375 @default.
• W4313509721 creator A5026647245 @default.
• W4313509721 creator A5030087459 @default.
• W4313509721 creator A5036235456 @default.
• W4313509721 creator A5036693647 @default.
• W4313509721 creator A5041100076 @default.
• W4313509721 creator A5042053222 @default.
• W4313509721 creator A5042386888 @default.
• W4313509721 creator A5049128352 @default.
• W4313509721 creator A5050011518 @default.
• W4313509721 date "2023-01-05" @default.
• W4313509721 modified "2023-10-14" @default.
• W4313509721 title "Identification of NS2B-NS3 Protease Inhibitors for Therapeutic Application in ZIKV Infection: A Pharmacophore-Based High-Throughput Virtual Screening and MD Simulations Approaches" @default.
• W4313509721 cites W1545235721 @default.
• W4313509721 cites W1561286863 @default.
• W4313509721 cites W1966628904 @default.
• W4313509721 cites W1975120587 @default.
• W4313509721 cites W1982842980 @default.
• W4313509721 cites W1983046030 @default.
• W4313509721 cites W1985588649 @default.
• W4313509721 cites W2011697200 @default.
• W4313509721 cites W2012156061 @default.
• W4313509721 cites W2028198504 @default.
• W4313509721 cites W2032850239 @default.
• W4313509721 cites W2041189078 @default.
• W4313509721 cites W2042474710 @default.
• W4313509721 cites W2042530028 @default.
• W4313509721 cites W2046336719 @default.
• W4313509721 cites W2053992388 @default.
• W4313509721 cites W2057926391 @default.
• W4313509721 cites W2068264550 @default.
• W4313509721 cites W2069632834 @default.
• W4313509721 cites W2074473216 @default.
• W4313509721 cites W2074942415 @default.
• W4313509721 cites W2102377211 @default.
• W4313509721 cites W2122349387 @default.
• W4313509721 cites W2152480222 @default.
• W4313509721 cites W2152546486 @default.
• W4313509721 cites W2164270482 @default.
• W4313509721 cites W2175028436 @default.
• W4313509721 cites W2237100413 @default.
• W4313509721 cites W2263907004 @default.
• W4313509721 cites W2295082417 @default.
• W4313509721 cites W2460267092 @default.
• W4313509721 cites W2461333390 @default.
• W4313509721 cites W2474204065 @default.
• W4313509721 cites W2511346829 @default.
• W4313509721 cites W2517471308 @default.
• W4313509721 cites W2549686806 @default.
• W4313509721 cites W2586096628 @default.
• W4313509721 cites W2587514484 @default.
• W4313509721 cites W2593954251 @default.
• W4313509721 cites W2610621214 @default.
• W4313509721 cites W2610740470 @default.
• W4313509721 cites W2663844394 @default.
• W4313509721 cites W2742713790 @default.
• W4313509721 cites W2765948825 @default.
• W4313509721 cites W2766643654 @default.
• W4313509721 cites W2768773884 @default.
• W4313509721 cites W2806583121 @default.
• W4313509721 cites W2809385362 @default.
• W4313509721 cites W2999431688 @default.
• W4313509721 cites W3000299205 @default.
• W4313509721 cites W366357061 @default.
• W4313509721 cites W4210967474 @default.
• W4313509721 cites W4281392792 @default.
• W4313509721 doi "https://doi.org/10.3390/vaccines11010131" @default.
• W4313509721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36679976" @default.
• W4313509721 hasPublicationYear "2023" @default.
• W4313509721 type Work @default.
• W4313509721 citedByCount "8" @default.
• W4313509721 countsByYear W43135097212023 @default.
• W4313509721 crossrefType "journal-article" @default.
• W4313509721 hasAuthorship W4313509721A5003144386 @default.
• W4313509721 hasAuthorship W4313509721A5010154794 @default.
• W4313509721 hasAuthorship W4313509721A5012496375 @default.
• W4313509721 hasAuthorship W4313509721A5026647245 @default.
• W4313509721 hasAuthorship W4313509721A5030087459 @default.
• W4313509721 hasAuthorship W4313509721A5036235456 @default.
• W4313509721 hasAuthorship W4313509721A5036693647 @default.
• W4313509721 hasAuthorship W4313509721A5041100076 @default.
• W4313509721 hasAuthorship W4313509721A5042053222 @default.
• W4313509721 hasAuthorship W4313509721A5042386888 @default.
• W4313509721 hasAuthorship W4313509721A5049128352 @default.
• W4313509721 hasAuthorship W4313509721A5050011518 @default.
• W4313509721 hasBestOaLocation W43135097211 @default.
• W4313509721 hasConcept C103697762 @default.
• W4313509721 hasConcept C104317684 @default.
• W4313509721 hasConcept C132379496 @default.
• W4313509721 hasConcept C159047783 @default.
• W4313509721 hasConcept C161624437 @default.
• W4313509721 hasConcept C2522874641 @default.
• W4313509721 hasConcept C2775905019 @default.
• W4313509721 hasConcept C2776408679 @default.

• next